OBJECTIVE: The primary objective of this study was to evaluate the race-specific risk associated with HER2/neu positive breast carcinoma in a prospective cohort design. Our secondary objectives were to assess prevalence of different breast cancer phenotypes between African-American and White women and to determine if race was associated with the risk of basal-like breast carcinoma phenotype in this cohort. METHODS: Demographic, clinical and pathologic data were collected from existing databases. The status of HER2/neu and hormone receptors was dichotomized as either positive or negative. Immunohistochemistry taxonomy was used to assess prevalence of different breast carcinoma phenotypes. Risk estimates were calculated using the multivariable logistic regression statistics. CONCLUSIONS: The risk of HER2/neu positive breast carcinoma differs between African-American and White women. For White women only, this risk was statistically significant and increased almost linearly within each TNM stage with grade dedifferentiation. The statistically significantly higher prevalence of "ER(-)/PR(-), HER2(- )" phenotype in African American women potentially is the attributing factor to observed lack of an association between the risk of HER2/neu positive breast carcinoma with advanced stages and poorly differentiated grade. Among women diagnosed with "ER(-)/PR(-), HER2(-)" phenotype the odds ratios of being African-American and pre-menopausal was 1.72 (95% CI 1.17-2.54, P = 0.006) and 1.94 (95% CI 1.27-2.96, P = 0.002), respectively. The histologic features of basal-like and ER(-)/HER2(+ )carcinomas overlaps. Differences in the biology of breast carcinoma between African American and White women are partially attributed to the disparity in more adverse pathologic prognostic indicators at the initial clinical presentation of this disease.
OBJECTIVE: The primary objective of this study was to evaluate the race-specific risk associated with HER2/neu positive breast carcinoma in a prospective cohort design. Our secondary objectives were to assess prevalence of different breast cancer phenotypes between African-American and White women and to determine if race was associated with the risk of basal-like breast carcinoma phenotype in this cohort. METHODS: Demographic, clinical and pathologic data were collected from existing databases. The status of HER2/neu and hormone receptors was dichotomized as either positive or negative. Immunohistochemistry taxonomy was used to assess prevalence of different breast carcinoma phenotypes. Risk estimates were calculated using the multivariable logistic regression statistics. CONCLUSIONS: The risk of HER2/neu positive breast carcinoma differs between African-American and White women. For White women only, this risk was statistically significant and increased almost linearly within each TNM stage with grade dedifferentiation. The statistically significantly higher prevalence of "ER(-)/PR(-), HER2(- )" phenotype in African American women potentially is the attributing factor to observed lack of an association between the risk of HER2/neu positive breast carcinoma with advanced stages and poorly differentiated grade. Among women diagnosed with "ER(-)/PR(-), HER2(-)" phenotype the odds ratios of being African-American and pre-menopausal was 1.72 (95% CI 1.17-2.54, P = 0.006) and 1.94 (95% CI 1.27-2.96, P = 0.002), respectively. The histologic features of basal-like and ER(-)/HER2(+ )carcinomas overlaps. Differences in the biology of breast carcinoma between African American and White women are partially attributed to the disparity in more adverse pathologic prognostic indicators at the initial clinical presentation of this disease.
Authors: Azadeh Stark; Celina G Kleer; Iman Martin; Baffour Awuah; Anthony Nsiah-Asare; Valerie Takyi; Maria Braman; Solomon E Quayson; Richard Zarbo; Max Wicha; Lisa Newman Journal: Cancer Date: 2010-11-01 Impact factor: 6.860
Authors: Amanda I Phipps; Rowan T Chlebowski; Ross Prentice; Anne McTiernan; Jean Wactawski-Wende; Lewis H Kuller; Lucile L Adams-Campbell; Dorothy Lane; Marcia L Stefanick; Mara Vitolins; Geoffrey C Kabat; Thomas E Rohan; Christopher I Li Journal: J Natl Cancer Inst Date: 2011-02-23 Impact factor: 13.506
Authors: Amanda I Phipps; Kathleen E Malone; Peggy L Porter; Janet R Daling; Christopher I Li Journal: Cancer Epidemiol Biomarkers Prev Date: 2008-07-29 Impact factor: 4.254
Authors: Christopher I Li; Elisabeth F Beaber; Mei-Tzu Chen Tang; Peggy L Porter; Janet R Daling; Kathleen E Malone Journal: Breast Cancer Res Treat Date: 2012-12-09 Impact factor: 4.872
Authors: Mohammed S Fayaz; Mustafa S El-Sherify; Amany El-Basmy; Sadeq A Zlouf; Nashwa Nazmy; Thomas George; Susan Samir; Gerges Attia; Heba Eissa Journal: Rep Pract Oncol Radiother Date: 2013-09-26
Authors: Christine Leopold; Anita K Wagner; Fang Zhang; Christine Y Lu; Craig Earle; Larissa Nekhlyudov; Dennis Ross-Degnan; J Frank Wharam Journal: Breast Cancer Res Treat Date: 2016-06-24 Impact factor: 4.872
Authors: Katrina F Trivers; Mary Jo Lund; Peggy L Porter; Jonathan M Liff; Elaine W Flagg; Ralph J Coates; J William Eley Journal: Cancer Causes Control Date: 2009-04-03 Impact factor: 2.506
Authors: Marilyn L Kwan; Lawrence H Kushi; Erin Weltzien; Benjamin Maring; Susan E Kutner; Regan S Fulton; Marion M Lee; Christine B Ambrosone; Bette J Caan Journal: Breast Cancer Res Date: 2009-05-22 Impact factor: 6.466